In the News

Laboratory for Advanced Medicine finance chief Aarif Nakhooda thinks customer experience is as important for colon cancer testing as it is for streaming online music or videos.

Early detection is a critical means of improving outcomes for cancer patients. When cancer is detected at stage I, patients have a 90 percent chance of survival. By contrast, if cancer is diagnosed at stage IV, patients have just a 5 percent or survival. The use of costly and invasive diagnostic approaches have been a barrier to early detection, but new technology has the potential to change that. Laboratory for Advanced Medicine is developing a simple blood-based test to detect cancer at its ea

The early detection of cancer has been proven to significantly improve patient survival rates and quality of life, as well as reduces the cost and complexity of cancer treatment. Therefore, the discovery and development of novel biomarkers are in critical need for the screening and surveillance of high-risk populations to enable prompt and successful treatment. Although traditional biopsies have been an integral part of cancer care for decades, biopsies are invasive, may induce complications and

Kenneth Chahine, PhD, J.D., Discusses Company’s First Liquid Biopsy, Designed to Detect Liver Cancer at Earliest Stages, and Plans to Test for Other Cancers.

Kenneth discusses LAM's early cancer detection tests.

Circulating tumor DNA (ctDNA), which is DNA that has been shed from ruptured cancer cells into the patient’s bloodstream, has quickly emerged as a useful biomarker for numerous cancer types.

A team of researchers affiliated with a large number of institutions in China has used a machine-learning algorithm with cancer methylation signatures to diagnose colorectal cancer.

NEW YORK – The methylation profiles of circulating tumor DNA may help diagnose colorectal cancer as well as predict patient prognosis, findings that may form the basis of a new cancer test.

Today we discuss the dissemination of DNA-methylation-based tests for non-invasive detection of cancer. BioQuick News recently sat down with Dhruvajyoti Roy (photo), PhD, who is the Director of Technology at the Laboratory for Advanced Medicine Inc. (LAM).

The Laboratory for Advanced Medicine has raised $86 million to further develop its blood test that can detect liver cancer. Kenneth Chahine, Chief Executive Officer of the Laboratory for Advanced Medicine, joined Cheddar to discuss.

Laboratory for Advanced Medicine (LAM), which uses artificial intelligence to identify early stages of specific cancers, is making strides to be the next big name in Orange County’s growing cluster of genomic-focused firms that provide high-tech healthcare diagnostics services....

Kenneth Chahine is the man behind AncestryDNA, the direct-to-consumer genetic genealogy product with more than 15 million users.

With a new CEO at its helm, Laboratory for Advanced Medicine is preparing to take on the cancer-diagnostics market.

Laboratory for Advanced Medicine Inc. has raised $86 million and hired a chief executive to push new blood tests for cancer toward the market.

Richard Brand and Dr. Dhruvajyoti Roy of Laboratory for Advanced Medicine discuss the company’s blood test for early cancer detection.

FDA has granted breakthrough status to Laboratory for Advanced Medicine’s liver cancer liquid biopsy, the Irvine, California-based company said in a statement Tuesday.

A change is underway as a result of research and development into tools to detect and treat cancer early, offering patients a fighting chance and improving chances for success against the disease.

The great promise of liquid biopsy technology is in early cancer detection. That is, it's the great future promise. Right? This past month at the annual cancer conference, ASCO, we heard about one such flagship company announcing just which technology they were going to use to do it--DNA methylation.

Nasopharyngeal carcinoma (NPC) is predominantly diagnosed using invasive testing methods like endoscopic biopsy or tissue biopsy. However, new research presented at the 2019 ASCO Annual Meeting demonstrated that biomarkers have been identified for the early detection and monitoring of NPC using liquid biopsy.

For a decade, industry researchers hypothesized that markers, such as mutations, could accurately detect cancer. However, mutation-based approaches have proven to be highly inaccurate due to the randomness of DNA mutations that occur in cancer patients. Mutations can also differ from tumor to tumor, within the same tumor over time, and same tumor origin in different patients.

More than 4,700 people are diagnosed with cancer each day. About four in 10 Americans—40 percent of men and 38 percent of women—will be diagnosed with cancer at some point in their lifetime.

Using a proprietary test of cell-free DNA methylation markers, the Laboratory for Advanced Medicine (LAM), headquartered in Irvine, California, showed preliminary data demonstrating high sensitivity and high specificity in the early detection of NPC using its DNA methylation test (the IvyGene test).

Commercial-stage medical technology company Laboratory for Advanced Medicine (LAM) announced positive results from a new study that evaluated DNA methylation-based marker panel for early diagnosis of nasopharyngeal carcinoma (NPC).

When a cancer cell dies, its DNA is released into the blood. Once released this DNA is referred to as cell-free DNA (cfDNA). The cfDNA retains a DNA methylation pattern that corresponds to the cell it originated from. When a “normal” cell transforms into a cancer cell significant gene expression changes occur, and these alterations correlate to methylation pattern changes. It is therefore possible to differentiate between normal and cancer cells by detecting which sites within the DNA are methyl

One of the potential flaws of liquid biopsy tests that rely on the detection of tumour DNA in a patient’s blood is that the tumour has to grow to a sufficient size to shed appreciable quantities of genetic material, making detection at an early, relatively treatable stage of disease that much harder. Laboratory for Advanced Medicine, or LAM, reckons it has found a better way. Its IvyGene tests work by detecting methylation levels of DNA, a gene expression marker that correlates with cancer...

The Laboratory for Advanced Medicine (LAM), a biotechnology company headquartered in the US, offers non-invasive, early stage cancer detection tests that will use the IvyGene Platform. These IvyGene tests are based on detecting genomic DNA shed by cancer cells into the blood stream. By assessing cell-free DNA found in blood samples, the company can measure the extent to which methyl groups are present in DNA at certain locations in order to detect the presence of...

Laboratory for Advanced Medicine (LAM) says its plans for this year include developing and commercializing more of its early cancer detection tests, expanding its portfolio beyond the four for which it has achieved validation, as well as growing its commercial staff and moving into its new headquarters.

A new blood test could help detect cancer as early as stage one, and one Long Island doctor says it could also save lives. The IvyGene test requires a few vials of blood to tell you if you may already be developing cancer cells in your body.

WESTBURY, N.Y., Oct. 12, 2018 /PRNewswire/ — Integrative Medicine of NY is one of the first clinical cancer facilities in the lower NY area to endorse and use the early detection and prevention lab test called IVYGENE. IMNY medical director Dr. Jesse Stoff is one of the first to support…

An international team of researchers at University of California San Diego School of Medicine and Moores Cancer Center, with colleagues at Sun Yet-sun University Cancer Center and other collaborating institutions, have developed a new diagnostic and prognosis method for early detection of hepatocellular carcinoma (HCC), based on a simple blood…

“…the term ‘cancer’ is not a singular enemy; its a single term to represent hundreds of different cancer types– all unique to their location in the body and their origin, and that makes screening/treating them a very specialized and a highly customized procedure.”  Howard Prince, research specialist & patient advocate…

During this year’s AACR annual meeting we spoke to Kang Zhang, M.D., Ph.D., Founding Director of the Genomic Institute at the University of California, San Diego about the collaborative work he has been doing with the Laboratory for Advanced Medicine (LAM). Their recent study findings on the use of a…

By now you may know that there are MANY options for detecting Breast Cancer outside of traditional mammography, which may come with some dangerous side effects. One option that I have written about in the past is the Oncoblot test, created by Dr. Dorothy Morré and the late Dr. James…

While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route – some further down the road than…

Mission will soon begin testing their firefighters for cancer. The Mission City Council authorized the purchase of IvyGene tests, a blood test that can detect the presence of certain diseases, including colon, liver and lung cancer. “We’re doing this for the firefighters obviously because of their working environment and what…

Liver cancer can be caught at an early stage through a newly developed blood test, improving the odds for survival, according to a study led by University of California San Diego scientists. The test looks for changed gene activity, caused by a process called methylation, that indicate liver cancer, said…

An international team of researchers at University of California San Diego School of Medicine and Moores Cancer Center, with colleagues at Sun Yet-sun University Cancer Center and other collaborating institutions, have developed a new diagnostic and prognosis method for early detection of hepatocellular carcinoma (HCC), based on a simple blood sample containing circulating tumor DNA.